Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9431750 | 0.98 | KDM4E (0.54) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL12569582 | 0.79 | CA12 (0.47) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1438126 | 0.76 | CA12 (0.44) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2819163 | 0.76 | CA12 (0.58) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL3140886 | 0.76 | CA12 (0.58) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL3224071 | 0.73 | CA12 (0.60) | KDM4EALDH1A1HPGDHSD17B10CA12 | |
| SCHEMBL12559639 | 0.72 | CA9 (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL11140695 | 0.72 | KDM4E (1.00) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL917801 | 0.71 | TNF (0.39) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL6880879 | 0.71 | KDM4E (0.54) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | KDM4E 1215/4885ALDH1A1 2216/4885GLA 658/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | KDM4E 1069/4885ALDH1A1 2732/4885GLA 1267/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | KDM4E 1215/4885ALDH1A1 2216/4885GLA 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.